FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular…
Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for Lunsumio (mosunetuzumab),…
Read More...
Read More...